Skip to main content

Table 2 Comparison of changes in body weight and metabolic parameters over time, between the antipsychotic-naïve and previous antipsychotic-use groups

From: Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments

Variable increase

Antipsychotic-naïve group

Previous antipsychotic-use group

Z

P

ES

Weight (kg)

 Week 4

2.84±3.35

1.59±2.49

3.29

<0.001

0.297

 Week 6

4.24±3.90

2.22±3.35

4.53

<0.001

0.296

BMI (kg/m2)

 Week 4

0.73±1.76

0.28±0.67

2.83

0.005

0.298

 Week 6

1.77±2.37

1.30±0.88

4.31

<0.001

0.296

Cholesterol (mmol l−1)

 Week 4

0.15±1.35

0.31±1.19

-0.96

0.338

0.302

 Week 6

0.45±0.91

0.35±0.92

0.86

0.391

0.300

Triglyceride (mmol l−1)

 Week 4

0.59±1.08

0.71±0.92

0.02

0.984

0.301

 Week 6

0.68±0.65

0.61±1.10

0.70

0.486

0.300

HDL-C (mmol l−1)

 Week 4

-0.11±0.44

-0.04±0.55

-0.90

0.369

0.302

 Week 6

0.00±0.41

-0.03±0.33

0.26

0.435

0.301

LDL-C (mmol l−1)

 Week 4

0.06 ±0.85

0.30±0.81

-2.19

0.030

0.303

 Week 6

0.23±0.67

0.56±0.75

-3.89

<0.001

0.306

Fasting glucose (mmol l−1)

 Week 4

-0.13±1.06

0.00±1.03

-0.92

0.358

0.302

 Week 6

0.20±0.74

0.04±0.81

1.67

0.096

0.299

  1. HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol